FENC:NASDAQ, Fennec Pharmaceuticals Inc.
FENC stock overview
Fennec Pharmaceuticals Inc. (FENC:NASDAQ) closed at $13.58 on November 17, 2026,
up 6.43% on the day.
The stock trades 0.4% below its 52-week high of $13.64
and 140.4% above its 52-week low of $5.65.
Over the past year, it gained 55.2%.
Fennec Pharmaceuticals Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
Key figures
- Price
- $13.58
- Day change
- +6.43%
- Volume
- 907,854
- Average volume
- 195,762
- Market cap
- 479M+
- 52-week range
- $5.65 – $13.64
- 50-day average
- $10.65
- 200-day average
- $9.38
Price action over the past year
In 252 trading sessions since November 17, 2025, FENC closed higher on 133 days (53%).
Its best day was May 14, 2026 (+36.48%) and its worst was March 24, 2026 (-19.19%).
The stock moved 10% or more in a single session 5 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
FENC news
-
Nov 17, 2026:
Adherex Technologies (FENC) is on the Move, Here's Why the Trend Could be Sustainable
-
Nov 13, 2026:
What Makes Adherex Technologies (FENC) a New Strong Buy Stock
-
Nov 13, 2026:
How Much Upside is Left in Adherex Technologies (FENC)? Wall Street Analysts Think 57.8%
-
Nov 12, 2026:
Adherex Technologies Q3 Earnings Call Highlights
-
Nov 12, 2026:
Fennec Pharma (FENC) Q3 2026 Earnings Call Transcript
-
Nov 12, 2026:
Fennec Pharmaceuticals Converts PEDMARK Momentum Into A 30% EBITDA Margin, Even As Year-Over-Year Growth Cools And Guidance Stays Absent
-
Nov 12, 2026:
Adherex Technologies Inc. (FENC) Q3 Earnings and Revenues Beat Estimates
-
Nov 12, 2026:
Fennec Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities.
Similar stocks
Find more stocks like FENC with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.